Tag archive

Pharmacosmos

Pharmacosmos’ PHOSPHARE study program demonstrates a safety advantage of iron isomaltoside

in Pharmaceutical News
Pharmacosmos' PHOSPHARE study program demonstrates a safety advantage of iron isomaltoside in relation to hypophosphatemia and other FGF23-mediated effects

Pharmacosmos announces the first results of the PHOSPHARE study program in which iron isomaltoside was compared directly to ferric carboxymaltose in two identical randomized controlled trials. Iron isomaltoside 1000 and ferric carboxymaltose are intravenous iron preparations that can be administered in high doses to rapidly treat iron deficiency and iron deficiency anemia. Ferric carboxymaltose has been shown to cause hypophosphatemia via urinary phosphate wasting due to elevations in the phosphate-regulating hormone fibroblast growth factor FGF23. Ferric carboxymaltose-induced hypophosphatemia has been…

Keep Reading

Iron isomaltoside and ferric carboxymaltose on hypophosphatemic effects in a controlled trial

in Pharmaceutical News
Press release: New study demonstrates significant difference between iron isomaltoside and ferric carboxymaltose on hypophosphatemic effects in a controlled, randomized clinical investigation

Results of a study comparing the incidence of hypophosphatemia after high dose IV iron substitution have been presented at the 60th annual meeting of the American Society of Hematology. The HOMe aFers trial recruited women with gynaecological bleeding and subsequent iron deficiency. All subjects were given high dose intravenous iron, randomised between iron isomaltoside and ferric carboxymaltose to correct their iron deficiency. It has been reported[1] that ferric carboxymaltose has a propensity to induce hypophosphatemia. This independent study was conducted…

Keep Reading

Go to Top